Drug Profile
INO 4212
Alternative Names: INO4212; VGX 4212Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Inovio Pharmaceuticals
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Ebola virus infections
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Ebola-virus-infections(Monotherapy, Prevention, In volunteers) in USA (IM, Injection)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Ebola-virus-infections(Combination therapy, Prevention, In volunteers) in USA (IM, Injection)
- 15 Oct 2018 Pharmacodynamics and immunogenicity data from preclinical trials in Ebola virus infections released by Inovio Pharmaceuticals